You are here: Home » 2024 » November » Archives for 13th

Duck Creek Estabelece Centro de Excelência na Polônia para Aprimorar Suporte Global aos Clientes

WARSAW, Polônia, Nov. 13, 2024 (GLOBE NEWSWIRE) — A Duck Creek Technologies, provedora global de soluções inteligentes que definem o futuro do seguro de propriedades e acidentes (P&C) e geral, anuncia a inauguração do seu segundo Centro de Excelência (CoE) em Varsóvia, Polônia. O novo COE, juntamente com o da Índia, fortalece a capacidade da Duck Creek de apoiar os clientes da EMEA e da APAC, com a utilização de talentos internacionais para fornecer atendimento 24 horas ao cliente. Esse evento ressalta o compromisso da Duck Creek atender com eficiência às necessidades locais e, ao mesmo tempo, ampliar o alcance global.

A Duck Creek tem como meta atingir o total status operacional até o final do ano. Este novo centro amplia a fonte de contratação da Duck Creek, fornecendo acesso a habilidades especializadas que apoiam o crescimento e o sucesso a longo prazo.

A localização estratégica da Polônia permite que a Duck Creek ofereça suporte contínuo e ininterrupto (follow–the–sun), posicionando as equipes mais próximas dos clientes da EMEA e da APAC e facilitando a colaboração entre fusos horários. Os CoEs da Polônia e da Índia trabalharão juntos para aumentar a resiliência e oferecer suporte consistente aos clientes da Duck Creek.

“Estamos muito empolgados com a expansão da nossa presença na Polônia pois isso é um testemunho da nossa dedicação ao aproveitamento do talento global e incentivo à inovação em suporte às nossas soluções de seguro na nuvem para os clientes em todo o mundo”, disse Courtney Townsend, Diretora de Recursos Humanos da Duck Creek Technologies. “O nosso novo Centro de Excelência na Polônia é um marco fundamental na nossa expansão europeia pois está alinhado com o nosso objetivo de agilizar as operações, dando continuidade ao fornecimento dos nossos excepcionais produtos e serviços.”

O COE da Polônia se concentra em soluções personalizadas para o mercado de seguros da EMEA e outros. Juntamente com o suporte técnico e de engenharia, o COE hospeda uma série de funções, incluindo desenvolvimento, testes e suporte ao cliente. O COE empregará inicialmente talentos em funções de Engenharia, Produto, Finanças/Contabilidade e TI, aproveitando a força de trabalho qualificada da Polônia para atender aos altos padrões de serviço em todas as regiões.

Ambos os CoEs são essenciais para as operações internacionais da Duck Creek. A abordagem dual–CoE aprimora a capacidade da Duck Creek de distribuir o trabalho de forma eficaz, gerenciar os riscos associados à escassez de talentos ou eventos geopolíticos, e aprimorar o atendimento ao cliente em todo o mundo.

Sobre a Duck Creek Technologies

A Duck Creek Technologies é fornecedora global de soluções inteligentes que definem o futuro do setor de seguros de propriedade e acidentes (P&C) e geral. Somos a plataforma utilizadas como base dos sistemas de seguros modernos, permitindo que a indústria capitalize o poder da nuvem para executar operações ágeis, inteligentes e perenes. Autenticidade, propósito e transparência são fundamentais para a Duck Creek, e acreditamos que o seguro deve estar disponível para indivíduos e empresas quando, onde e como eles mais precisarem. Nossas soluções líderes do mercado estão disponíveis de forma independente ou como um pacote completo disponíveis em Duck Creek OnDemand. Visite www.duckcreek.com para obter mais informação. Siga a Duck Creek nas nossas redes sociais para obter as mais recentes informações – LinkedIn e X.

Contato com a Mídia

Marianne Dempsey/Tara Stred
duckcreek@threeringsinc.com


GLOBENEWSWIRE (Distribution ID 9273231)

Duck Creek gründet Kompetenzzentrum in Polen zur Verbesserung der Unterstützung von Kunden weltweit

WARSCHAU, Polen, Nov. 13, 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, der globale Anbieter intelligenter Lösungen, der die Zukunft der Sach– und Unfallversicherung sowie der allgemeinen Versicherung gestaltet, hat die Eröffnung seines zweiten Kompetenzzentrums (Center of Excellence, CoE) in Warschau, Polen, bekanntgegeben. Das neue Kompetenzzentrum stärkt zusammen mit dem in Indien die Fähigkeit von Duck Creek, Kunden in den EMEA– und APAC–Regionen zu unterstützen, indem es internationale Talente nutzt, um einen 24–Stunden–Kundendienst bereitzustellen. Dieser Schritt unterstreicht das Engagement von Duck Creek, lokale Bedürfnisse effizient zu erfüllen und gleichzeitig die globale Reichweite auszuweiten.

Duck Creek strebt an, bis zum Jahresende die volle Betriebsbereitschaft zu erreichen. Dieses neue Zentrum erweitert den Einstellungspool von Duck Creek und bietet Zugang zu Fachkenntnissen, die langfristiges Wachstum und Erfolg unterstützen.

Dank der strategischen Lage Polens kann Duck Creek einen nahtlosen „Follow–the–Sun“–Support bieten, die Teams näher an den EMEA– und APAC–Kunden positionieren und die Zusammenarbeit über Zeitzonen hinweg erleichtern. Die Kompetenzzentren in Polen und Indien werden zusammenarbeiten, um die Resilienz zu verbessern und den Kunden von Duck Creek durchgängige Unterstützung zu bieten.

„Wir freuen uns, unsere Präsenz in Polen auszubauen. Dies ist ein Beweis für unser Engagement, globale Talente zu nutzen und Innovationen zu fördern, um unsere cloudbasierten Versicherungslösungen für Kunden weltweit zu unterstützen“, so Courtney Townsend, Chief People Officer von Duck Creek Technologies. „Unser neues Kompetenzzentrum in Polen stellt einen entscheidenden Meilenstein unserer europäischen Expansion dar und steht im Einklang mit unserem Ziel, die Betriebsabläufe zu rationalisieren und gleichzeitig weiterhin außergewöhnliche Produkte und Dienstleistungen bereitstellen zu können.“

Das polnische Kompetenzzentrum konzentriert sich auf maßgeschneiderte Lösungen für den EMEA–Versicherungsmarkt und darüber hinaus. Neben dem technischen und entwicklungstechnischen Support bietet das Kompetenzzentrum eine Reihe von Funktionen, darunter Entwicklung, Tests und Kundensupport. Das Kompetenzzentrum wird zunächst Talente in den Bereichen Entwicklung, Produkte, Finanzen/Buchhaltung und IT einstellen und dabei auf die qualifizierten Arbeitskräfte Polens zurückgreifen, um in allen Regionen hohe Servicestandards erfüllen zu können.

Beide Kompetenzzentren sind für die internationalen Aktivitäten von Duck Creek von entscheidender Bedeutung. Der Ansatz mit zwei Kompetenzzentren verbessert die Fähigkeit von Duck Creek, Arbeit effektiv zu verteilen, Risiken im Zusammenhang mit Talentmangel oder geopolitischen Ereignissen zu managen und den Kundendienst weltweit zu stärken.

Über Duck Creek Technologies

Duck Creek Technologies ist der globale Anbieter von intelligenten Lösungen, die die Zukunft der Schaden– und Unfall– und allgemeinen Versicherungsbranche definieren. Wir sind die Plattform, auf der moderne Versicherungssysteme aufgebaut werden und die es der Branche ermöglicht, die Leistungsfähigkeit der Cloud zu nutzen, um agile, intelligente und zukunftssichere Prozesse zu betreiben. Authentizität, Zweckmäßigkeit und Transparenz sind für Duck Creek von zentraler Bedeutung. Wir sind der Meinung, dass Versicherungen für Privatpersonen und Unternehmen verfügbar sein sollten, wann, wo und wie sie diese am meisten benötigen. Unsere marktführenden Lösungen sind als Einzellösungen oder als komplette Suite erhältlich. Alle sind über Duck Creek OnDemand verfügbar. Besuchen Sie www.duckcreek.com, um mehr zu erfahren. Folgen Sie Duck Creek auf unseren sozialen Kanälen für die neuesten Informationen – LinkedIn und X.

Medienkontakt

Marianne Dempsey/Tara Stred
duckcreek@threeringsinc.com


GLOBENEWSWIRE (Distribution ID 9273231)

Duck Creek établit un centre d’excellence en Pologne en vue d’améliorer l’assistance client à l’échelle mondiale

VARSOVIE, Pologne, 13 nov. 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, le fournisseur mondial de solutions intelligentes qui dessine les futurs contours du secteur de l’assurance générale et IARD (incendies, accidents et risques divers), a annoncé l’ouverture de son deuxième centre d’excellence (CoE) à Varsovie, en Pologne. Ce nouveau centre d’excellence, qui vient s’ajouter à celui basé en Inde, permet de renforcer les capacités de Duck Creek en matière d’assistance client pour les régions EMOA et APAC en s’appuyant sur des talents internationaux pour proposer un service client disponible 24 heures sur 24. Cette initiative vient souligner l’engagement de Duck Creek à répondre efficacement aux besoins locaux tout en élargissant sa présence à l’international.

Duck Creek prévoit d’être pleinement opérationnel d’ici la fin de l’année. Ce nouveau centre permet d’élargir la politique de recrutement de Duck Creek en donnant accès à des compétences spécialisées qui favorisent la croissance et la réussite à long terme.

L’emplacement stratégique de la Pologne permet à Duck Creek d’offrir une assistance sans faille et en continu, en rapprochant les équipes des clients résidant dans les régions EMOA et APAC et en facilitant la collaboration entre les différents fuseaux horaires. Les centres d’excellence de Pologne et d’Inde travailleront de concert pour renforcer la résilience et fournir une assistance constante aux clients de Duck Creek.

« Nous sommes ravis d’étendre notre présence en Pologne. Cela témoigne de notre engagement à exploiter les talents à l’international et à encourager l’innovation pour renforcer nos solutions d’assurance basées sur le cloud destinées aux clients du monde entier », a déclaré Courtney Townsend, Directeur des ressources humaines chez Duck Creek Technologies. « Notre nouveau centre d’excellence en Pologne marque une étape décisive dans notre expansion européenne et s’inscrit dans notre objectif de rationalisation des opérations tout en continuant à fournir des produits et des services hors du commun. »

Le centre d’excellence basé en Pologne se concentre sur des solutions sur mesure destinées au marché de l’assurance de la région EMOA et au–delà. Outre l’assistance technique et d’ingénierie, le centre d’excellence héberge un ensemble de fonctions, notamment le développement, les tests et l’assistance client. Dans un premier temps, le centre d’excellence emploiera des talents dans les domaines de l’ingénierie, des produits, de la finance/comptabilité et de l’informatique, en s’appuyant sur une main–d’œuvre polonaise qualifiée qui permettra de se conformer aux normes exigeantes de toutes les régions.

Les deux centres d’excellence sont essentiels aux activités internationales de Duck Creek. Cette approche basée sur deux centres d’excellence permet d’améliorer la capacité de Duck Creek à répartir le travail de manière efficace, à gérer les risques liés à la pénurie de talents ou aux événements géopolitiques, et à renforcer l’assistance client dans le monde entier.

À propos de Duck Creek Technologies

Duck Creek Technologies est le fournisseur mondial de solutions intelligentes qui trace les futurs contours du secteur de l’assurance générale et IARD (incendies, accidents et risques divers). Les systèmes d’assurance modernes reposent sur nos solutions et exploitent le potentiel du cloud pour mener des opérations flexibles, intelligentes et évolutives. Authenticité, détermination et transparence, voilà les maîtres–mots de la philosophie de Duck Creek. Pour nous, l’assurance est au service des particuliers et des entreprises, au moment, à l’endroit et de la manière dont ils en ont le plus besoin. Nos solutions, leaders du marché, sont commercialisées à l’unité ou sous forme de suite packagée, et sont toutes disponibles sur la page : Duck Creek OnDemand. Pour en savoir plus, consultez le site www.duckcreek.com. Suivez–nous sur les réseaux pour consulter nos actualités : LinkedIn et X.

Interlocutrices auprès des médias

Marianne Dempsey/Tara Stred
duckcreek@threeringsinc.com


GLOBENEWSWIRE (Distribution ID 9273231)

DEBx Medical sichert sich erweiterte Investition von TVM Capital Healthcare

DEBx Medical ist bereit für ein beschleunigtes Wachstum im Bereich der Lösungen für chronische Wunden, gestützt durch die zweite Investitionsrunde von TVM Capital Healthcare.

AMSTERDAM und DUBAI, Vereinigte Arabische Emirate, Nov. 13, 2024 (GLOBE NEWSWIRE) — DEBx Medical, ein in Amsterdam ansässiger, innovativer Pionier auf dem Gebiet der fortschrittlichen Wundversorgung, gibt den erfolgreichen Abschluss seiner zweiten Kapitalinvestitionsrunde unter der Leitung von TVM Capital Healthcare bekannt. Die Finanzierung wird die globale Expansion von DEBx Medical in die wichtigsten Märkte der Welt beschleunigen.

Die Investition folgt auf eine erfolgreiche erste Finanzierungsrunde und spiegelt das wachsende Vertrauen in den innovativen Ansatz von DEBx Medical im Bereich der Behandlung chronischer Wunden wider, insbesondere durch die bahnbrechende Lösung DEBRICHEM®, ein topisches Austrocknungsmittel zur Beseitigung von Biofilm und Infektionen in chronischen Wunden.

Globale Marktexpansion wird die Versorgung chronischer Wunden verändern

Diese zweite Investitionsrunde wird die Strategie des Unternehmens unterstützen, in die stark regulierten und wettbewerbsintensiven Märkte zu expandieren und die Mission von DEBx Medical zu unterstützen, das Management chronischer Wunden zu verändern und die Ergebnisse für die Patienten zu verbessern.

Chronische Wunden stellen weltweit eine erhebliche Belastung für die Gesundheitssysteme dar, nicht nur wegen ihrer Häufigkeit, sondern auch wegen der damit verbundenen Kosten, Komplikationen und der Beeinträchtigung der Lebensqualität der Patienten.

DEBRICHEM® bietet eine unvergleichliche Lösung zur vollständigen Beseitigung von Biofilm und Infektionen in chronischen Wunden. Mit den erhaltenen CE– und ISO–Zertifizierungen hat das Unternehmen seit seiner Markteinführung bereits Tausende von Patienten erfolgreich behandelt.

Anlegerperspektive

„Diese neue Finanzierungsrunde von TVM Capital Healthcare wird die weltweite Vermarktung von DEBRICHEM® beschleunigen und DEBx Medical in die Lage versetzen, mehr Patienten zu erreichen und das durch nicht heilende Wunden verursachte Leiden zu lindern“, so Tristan de Boysson, Managing Partner von TVM Capital Healthcare. „Wir halten auch an der Strategie des TVM Healthcare Afiyah Fund fest, innovative Lösungen in die MENA–Region zu bringen, insbesondere in das Königreich Saudi–Arabien, und freuen uns auf die Zusammenarbeit mit diesem beeindruckenden Team, um diese Ziele zu erreichen.“

Die erneute Investition von TVM Capital Healthcare wird DEBx Medical in die Lage versetzen, seine Vermarktungsbemühungen weiter auszubauen.

„Wir freuen uns, diesen wichtigen Schritt auf dem Weg der globalen Expansion von DEBx Medical zu machen“, so Bert Quint, CEO von DEBx Medical. „Diese Finanzierungsrunde wird es uns ermöglichen, in Schlüsselmärkte auf der ganzen Welt vorzudringen, in denen die Belastung durch chronische Wunden nach wie vor erheblich ist. Die Unterstützung unserer Investoren ist eine starke Bestätigung für das Potenzial unseres Produkts, die Wundversorgung weltweit zu verändern.“

Vorantreiben der Innovation in der Wundversorgung

DEBRICHEM® hat in Europa und in Teilen der MENA–Region, einschließlich im KSA, bereits große Erfolge erzielt und bietet medizinischen Fachkräften eine leistungsstarke Lösung zur Behandlung chronischer Wunden. Das Produkt hat bemerkenswerte Ergebnisse bei der Wiederaufnahme des Heilungsprozesses von Wunden gezeigt, bei denen Biofilm und Infektionen ein Hindernis darstellten.

DEBRICHEM®'s Mode of Action on Animated Wound Model: DEBRICHEM®

Ein Medien–Snippet zu dieser Ankündigung ist durch Anklicken dieses Links verfügbar.

Künftiges Wachstum und Entwicklung

Neben der Ausweitung seiner geografischen Reichweite plant DEBx Medical, seine Forschungs– und Entwicklungsbemühungen weiter voranzutreiben, um neue Lösungen für die Wundversorgung einzuführen. Die Konzentration des Unternehmens auf klinische Daten und evidenzbasierte Medizin wird auch weiterhin eine treibende Kraft sein, wenn es darum geht, sein Produktportfolio zu erweitern und den ungedeckten Bedarf in der Behandlung chronischer Wunden zu decken.

Über DEBx Medical

DEBx Medical hat es sich zur Aufgabe gemacht, die Wundversorgung durch innovative, wissenschaftlich fundierte Lösungen zu verbessern. Das 2019 gegründete Unternehmen hat es sich zur Aufgabe gemacht, das Leben von Patienten mit chronischen Wunden zu verbessern, indem es medizinischem Fachpersonal bahnbrechende Hilfsmittel zur effektiven Behandlung komplexer Wunden zur Verfügung stellt. DEBRICHEM®, das Vorzeigeprodukt des Unternehmens, ist ein topisches Trocknungsmittel, das Biofilm und Infektionen beseitigt und eine schnellere und effizientere Wundheilung fördert. Weitere Informationen finden Sie unter: DEBx Medical – Innovating The Future of Wound Care (debx–medical.com)

Über TVM Capital Healthcare

TVM Capital Healthcare ist ein weltweit tätiges Private–Equity–Unternehmen im Gesundheitswesen, das sich auf Schwellenländer spezialisiert hat. Das Unternehmen mit Hauptsitz in Dubai und Singapur und Niederlassungen in Riad, Boston, München und Ho–Chi–Minh–Stadt investiert Expansions– und Wachstumskapital in Unternehmen des Gesundheitswesens, um den lokalen Zugang zu qualitativ hochwertiger und erschwinglicher Versorgung zu verbessern, sowie in lokale Anbieter von medizinischen Produkten in den Bereichen Pharma, Medizintechnik und Diagnostik. Die Investitions– und Betriebspartner sowie eine starke Gruppe regionaler und internationaler Berater verfügen über eine langjährige Erfolgsbilanz bei Investitionen im Gesundheitswesen und über umfassende operative Erfahrung im Nahen Osten und in Südostasien. Für weitere Informationen besuchen Sie bitte: TVMCapitalHealthcare.com 

Für Medienanfragen wenden Sie sich bitte an:

DEBx Medical: Chandrita Jaisinghani, press@debx–medical.com, +31 85 0878096


GLOBENEWSWIRE (Distribution ID 1001013002)

DEBx Medical obtient de nouveaux investissements auprès de TVM Capital Healthcare

Grâce au deuxième tour d’investissement de TVM Capital Healthcare, DEBx Medical s’apprête à accélérer sa croissance dans le domaine des solutions de traitement des plaies chroniques.

AMSTERDAM et DUBAÏ, Émirats arabes unis, 13 nov. 2024 (GLOBE NEWSWIRE) — DEBx Medical, entreprise basée à Amsterdam et championne de l’innovation dans le domaine des soins avancés des plaies, annonce la réussite de son deuxième tour d’investissement de capitaux mené par TVM Capital Healthcare. Ce financement accélérera l’expansion internationale de DEBx Medical sur les principaux marchés mondiaux.

Faisant suite à un premier tour de financement réussi, l’investissement reflète la confiance croissante que suscite l’approche innovante de DEBx Medical en matière de gestion des plaies chroniques, notamment grâce à sa solution révolutionnaire, DEBRICHEM®. Cet agent dessiccant topique est utilisé pour éradiquer le biofilm et l’infection des plaies chroniques.

Un développement sur le marché international qui vise à transformer le traitement des plaies chroniques

Ce deuxième tour d’investissement soutient la stratégie de développement de l’entreprise sur les marchés réglementés et concurrentiels, et viendra ainsi soutenir davantage encore la mission que DEBx Medical s’est fixée en matière de transformation de la gestion des plaies chroniques et d’amélioration des résultats pour les patients.

Pour les systèmes de santé du monde entier, les plaies chroniques représentent un fardeau considérable, non seulement du fait de leur prévalence mais aussi en raison des coûts associés, des complications, et des impacts sur la qualité de vie des patients.

Parce qu’elle permet d’éradiquer complètement le biofilm et l’infection des plaies chroniques, DEBRICHEM® offre une solution inégalée. Après avoir obtenu les certifications CE et ISO, l’entreprise a pu soigner avec succès des milliers de patients depuis le lancement de son produit sur le marché.

Point de vue des investisseurs

« Ce nouveau tour de financement de TVM Capital Healthcare va accélérera la commercialisation de DEBRICHEM® dans le monde entier tout en permettant à DEBx Medical d’atteindre davantage de patients et de soulager les souffrances causées par des plaies non cicatrisantes », a commenté Tristan de Boysson, associé gérant de TVM Capital Healthcare. « Par ailleurs, nous nous engageons à nouveau dans la stratégie du fonds Afiyah de TVM Healthcare visant à apporter des solutions innovantes à la région MENA, en particulier au Royaume d’Arabie saoudite, et nous sommes impatients d’entamer notre collaboration avec cette équipe impressionnante en vue d’atteindre ces objectifs. »

Le renouvellement de l’investissement de TVM Capital Healthcare permettra à DEBx Medical d’élargir ses activités commerciales.

« Nous sommes ravis de franchir cette étape clé dans l’expansion mondiale de DEBx Medical », a déclaré Bert Quint, PDG de DEBx Medical. « Ce tour de financement nous permettra de pénétrer des marchés clés dans le monde entier, là où le fardeau des plaies chroniques reste important. Le soutien de nos investisseurs apporte une solide validation du potentiel de notre produit à transformer les pratiques de soins des plaies dans le monde entier. »

Stimuler l’innovation en matière de soin des plaies

En offrant aux professionnels de la santé une solution puissante pour le traitement des plaies chroniques, DEBRICHEM® a déjà eu un impact significatif en Europe et dans certaines régions de la région MENA, et notamment en Arabie saoudite. Le produit a en effet obtenu des résultats remarquables en contribuant à relancer le processus de cicatrisation des plaies malgré l’obstacle que constituent le biofilm et l’infection.

DEBRICHEM®'s Mode of Action on Animated Wound Model: DEBRICHEM®

Une coupure de presse accompagnant cette annonce est disponible en cliquant sur ce lien.

Croissance et développement futurs

En plus d’étendre sa présence géographique, DEBx Medical continuera ses activités de recherche et développement pour introduire de nouvelles solutions de traitement des plaies. L’entreprise privilégie les données cliniques et la médecine fondée sur des données probantes, et c’est ce même principe qui continuera d’animer sa démarche de développement de son portefeuille de produits en vue de répondre aux besoins non satisfaits en matière de traitement des plaies chroniques.

À propos de DEBx Medical

DEBx Medical consacre ses activités à la transformation du traitement des plaies grâce à des solutions innovantes et scientifiques. Fondée en 2019, l’entreprise s’est fixé pour mission d’améliorer la vie des patients souffrant de plaies chroniques en fournissant aux professionnels des outils révolutionnaires pour traiter efficacement les plaies complexes. Le produit phare de la société, DEBRICHEM®, est un agent dessiccant topique qui élimine le biofilm et l’infection, favorisant ainsi une cicatrisation plus rapide et plus efficace des plaies. Pour obtenir de plus amples informations, consultez cette page Internet : DEBx Medical – Innovating The Future of Wound Care (debx–medical.com)

À propos de TVM Capital Healthcare

TVM Capital Healthcare est une société mondiale de capital–investissement spécialisée dans les marchés émergents. Basée à Dubaï et à Singapour, la société possède des bureaux à Riyad, Boston, Munich et Ho Chi Minh–Ville. Afin d’améliorer l’accès local à des soins de santé de qualité et abordables, l’entreprise investit des capitaux d’expansion et de croissance dans des entreprises de soins de santé, ainsi que dans des sources locales de produits médicaux dans les secteurs des produits pharmaceutiques, des dispositifs médicaux et des solutions diagnostiques. Les partenaires d’investissement et d’exploitation, épaulés par un solide groupe de conseillers régionaux et internationaux expérimentés, possèdent une longue expérience en matière d’investissement dans le secteur de la santé et une solide expérience opérationnelle au Moyen–Orient et en Asie du Sud–Est. Pour obtenir de plus amples informations, consultez : TVMCapitalHealthcare.com 

Pour les demandes médias, veuillez contacter :

DEBx Medical : Chandrita Jaisinghani, press@debx–medical.com, +31 85 0878096


GLOBENEWSWIRE (Distribution ID 1001013002)

A DEBx Medical garante investimento expandido da TVM Capital Healthcare

A DEBx Medical está preparada para um crescimento acelerado em soluções para feridas crônicas, com o apoio da segunda rodada de investimento da TVM Capital Healthcare.

AMSTERDÃ e DUBAI, Emirados Árabes Unidos, Nov. 13, 2024 (GLOBE NEWSWIRE) — A DEBx Medical, uma líder inovadora com sede em Amsterdã na área de cuidados avançados de feridas, anuncia a bem–sucedida conclusão de sua segunda rodada de investimentos, liderada pela TVM Capital Healthcare. O financiamento acelerará a expansão global da DEBx Medical para os principais mercados ao redor do mundo.

O investimento segue uma bem–sucedida rodada inicial de financiamento e reflete a crescente confiança na abordagem inovadora da DEBx Medical para o tratamento de feridas crônicas, especialmente por meio de sua solução inovadora, DEBRICHEM®, um agente dIssecante tópico usado para erradicar biofilme e infecção de feridas crônicas.

A expansão global do mercado transformará o tratamento de feridas crônicas

Esta segunda rodada de investimento irá corroborar com a estratégia da empresa de se expandir para mercados altamente regulamentados e competitivos, fortalecendo ainda mais a missão da DEBx Medical de transformar o tratamento de feridas crônicas e melhorar os resultados dos pacientes.

As feridas crônicas impõem uma carga considerável aos sistemas de saúde em todo o mundo, não apenas devido à sua frequência, mas também aos custos associados, complicações e impactos na qualidade de vida dos pacientes.

O DEBRICHEM® oferece uma solução incomparável, erradicando completamente o biofilme e a infecção das feridas crônicas. Com as certificações CE e ISO obtidas, a empresa já tratou com sucesso milhares de pacientes desde sua introdução no mercado.

Perspectiva do investidor

“Esta nova rodada de financiamento da TVM Capital Healthcare acelerará a comercialização do DEBRICHEM® mundialmente e permitirá que a DEBx Medical alcance mais pacientes e alivie o sofrimento causado pelas feridas que não cicatrizam”, comentou Tristan de Boysson, sócio–gerente da TVM Capital Healthcare. “Também estamos reafirmando nosso compromisso com a estratégia do TVM Healthcare Afiyah Fund para levar soluções inovadoras à região MENA, particularmente ao Reino da Arábia Saudita, e esperamos trabalhar com essa equipe impressionante para alcançar esses objetivos.”

O investimento renovado da TVM Capital Healthcare permitirá ainda que a DEBx Medical amplie suas iniciativas de comercialização.

“Estamos entusiasmados em dar este importante passo na jornada da DEBx Medical em direção à expansão global”, disse Bert Quint, CEO da DEBx Medical. “Esta rodada de financiamento nos permitirá entrar nos principais mercados mundiais, onde o impacto das feridas crônicas ainda é significativo. O apoio dos nossos investidores é uma forte validação do potencial do nosso produto para transformar as práticas de cuidado de feridas em todo o mundo.”

Conduzindo a inovação no tratamento de feridas

O DEBRICHEM® já teve um impacto significativo na Europa e em partes da região MENA, incluindo a Arábia Saudita, oferecendo aos profissionais de saúde uma solução poderosa para tratar feridas crônicas. O produto tem mostrado resultados notáveis ao ajudar a reiniciar o processo de cicatrização em feridas onde o biofilme e a infecção eram uma barreira.

DEBRICHEM®'s Mode of Action on Animated Wound Model: DEBRICHEM®

Um trecho de mídia que acompanha este anúncio está disponível clicando neste link.

Crescimento e desenvolvimento futuro

Além de expandir seu alcance geográfico, a DEBx Medical planeja continuar avançando em seus esforços de pesquisa e desenvolvimento para introduzir novas soluções no cuidado de feridas. O foco da empresa em dados clínicos e medicina baseada em evidências continuará a ser um fator fundamental enquanto ela busca ampliar seu portfólio de produtos e atender às necessidades não atendidas no tratamento de feridas crônicas.

Sobre a DEBx Medical

A DEBx Medical é dedicada a transformar o tratamento de feridas por meio de soluções inovadoras e cientificamente fundamentadas. Fundada em 2019, a missão da empresa é melhorar a vida dos pacientes com feridas crônicas, fornecendo aos profissionais de saúde ferramentas revolucionárias para tratar feridas complexas de forma eficaz. O DEBRICHEM®, produto principal da empresa, é um agente dissecante tópico que elimina biofilme e infecção, promovendo uma cicatrização de feridas mais rápida e eficiente. Para mais informações, visite: DEBx Medical – Innovating The Future of Wound Care (debx–medical.com)

Sobre a TVM Capital Healthcare

A TVM Capital Healthcare é uma empresa global de capital privado especializada em saúde e com foco em mercados emergentes. Com sede em Dubai e Cingapura, e escritórios em Riade, Boston, Munique e na cidade de Ho Chi Minh, a empresa investe capital de expansão e crescimento em empresas de saúde para melhorar o acesso local a tratamentos de qualidade e acessíveis, além de fontes locais de produtos médicos nos setores farmacêutico, de dispositivos médicos e diagnósticos. Os parceiros de investimento e operação, assim como um robusto grupo de conselheiros seniores regionais e internacionais, possuem longos históricos de sucesso em investimentos no setor de saúde e vasta experiência operacional no Oriente Médio e Sudeste Asiático. Para mais informações, acesse: TVMCapitalHealthcare.com 

Para comunicação social, entre em contato com:

DEBx Medical: Chandrita Jaisinghani, press@debx–medical.com, +31 85 0878096


GLOBENEWSWIRE (Distribution ID 1001013002)

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.

AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 (GLOBE NEWSWIRE) — DEBx Medical, an Amsterdam–based pioneering innovator in the field of advanced wound care, announces the successful completion of its second capital investment round led by TVM Capital Healthcare. The funding will accelerate DEBx Medical’s global expansion into major markets around the world.

The investment follows a successful initial round of funding and reflects growing confidence in DEBx Medical’s innovative approach to chronic wound management, specifically through its breakthrough solution, DEBRICHEM®, a topical desiccating agent used to eradicate biofilm and infection from chronic wounds.

Global Market Expansion to Transform Chronic Wound Care

This second investment round will support the company’s strategy to expand into the highly regulated and competitive markets, further supporting DEBx Medical’s mission to transform the management of chronic wounds and improve patient outcomes.

Chronic wounds impose a considerable burden on healthcare systems world over, not just due to their prevalence but also due to the associated costs, complications, and impacts on patients' quality of life.

DEBRICHEM® offers an unparalleled solution completely eradicating biofilm and infection from chronic wounds, and with CE and ISO certifications obtained, the company has successfully treated thousands of patients since its market introduction.

Investor Perspective

“This new round of funding from TVM Capital Healthcare will accelerate the commercialization of DEBRICHEM® worldwide and enable DEBx Medical to reach more patients and alleviate the suffering caused by non–healing wounds,” commented Tristan de Boysson, Managing Partner of TVM Capital Healthcare. “We are also recommitting to the TVM Healthcare Afiyah Fund strategy to bring innovative solutions to the MENA region, particularly, in the Kingdom of Saudi Arabia, and look forward to working with this impressive team to achieve those objectives.”

TVM Capital Healthcare’s renewed investment will further enable DEBx Medical to expand its commercialization efforts.

“We are excited to take this important step in DEBx Medical’s journey toward global expansion,” said Bert Quint, CEO of DEBx Medical. “This round of funding will allow us to enter key markets around the world, where the burden of chronic wounds remains significant. Our investors’ support is a strong validation of our product’s potential to transform wound care practices worldwide.”

Driving Innovation in Wound Care

DEBRICHEM® has already made a significant impact in Europe and parts of the MENA region, including KSA, offering healthcare professionals a powerful solution to treat chronic wounds. The product has shown remarkable results in helping restart the healing process in wounds where biofilm and infection have been a barrier.

DEBRICHEM®'s Mode of Action on Animated Wound Model: DEBRICHEM®

A Media Snippet accompanying this announcement is available by clicking on this link.

Future Growth and Development

In addition to expanding its geographic reach, DEBx Medical plans to continue advancing its research and development efforts to introduce new solutions in wound care. The company’s focus on clinical data and evidence–based medicine will remain a driving force as it seeks to broaden its product portfolio and address unmet needs in chronic wound treatment.

About DEBx Medical

DEBx Medical is dedicated to transforming wound care through innovative, scientifically driven solutions. Founded in 2019, the company’s mission is to improve the lives of patients with chronic wounds by providing healthcare professionals with groundbreaking tools to treat complex wounds effectively. DEBRICHEM®, the company’s flagship product, is a topical desiccating agent that eliminates biofilm and infection, promoting faster and more efficient wound healing. For more information, visit: DEBx Medical – Innovating The Future of Wound Care (debx–medical.com)

About TVM Capital Healthcare

TVM Capital Healthcare is a global healthcare private equity firm specializing in emerging markets. Headquartered in Dubai and Singapore, with offices in Riyadh, Boston, Munich, and Ho Chi Minh City, the firm invests expansion and growth capital in healthcare companies to improve local access to quality and affordable care, as well as local sources of medical products in the pharma, medical device, and diagnostics sectors. Investment and operating partners, as well as a strong group of regional and international senior advisors, have long–standing track records in healthcare investing and deep operating experience in the Middle East and Southeast Asia. For more information visit: TVMCapitalHealthcare.com 

For media inquiries, please contact:

DEBx Medical: Chandrita Jaisinghani, press@debx–medical.com, +31 85 0878096


GLOBENEWSWIRE (Distribution ID 1001013002)

Blinded by Circumstance: Trachoma’s Stranglehold on Kenya’s Rural Pastoralists

Turkana women recover with white bandages over their eyes after undergoing surgery to treat trachoma, the world's leading cause of blindness. Efforts like these are crucial in preventing the spread of this debilitating disease in vulnerable communities. Credit: Robert Kibet/IPS

Turkana women recover with white bandages over their eyes after undergoing surgery to treat trachoma, the world’s leading cause of blindness. Efforts like these are crucial in preventing the spread of this debilitating disease in vulnerable communities. Credit: Robert Kibet/IPS

By Robert Kibet
ELANKATA ENTERIT, Kenya, Nov 13 2024 – Draped in the vibrant red of his Maasai shuka, 52-year-old Rumosiroi Ole Mpoke sits cross-legged on a worn cowhide mat outside his hut, his face etched with a sorrow deeper than the lines of age. His once-sharp eyes, now clouded by trachoma, can barely make out the shadows of the cattle he once tended with pride.

“I should have done something when I still could see,” he says quietly, his voice thick with regret. “Now, I am useless with my livestock, and my children must guide me around our land. I can no longer provide for them as a father should.”

In Elankata Enterit, Narok County, a remote village tucked 93 miles northwest of Nairobi, Rumosiroi has been stripped not only of his sight but of his role as a provider, now trapped in a cycle of poverty and dependence that gnaws at his spirit.

The Maasai, known for their resilience and deep bond with the land, are among Kenya’s pastoralist communities, particularly vulnerable to trachoma. The dusty, arid environment they inhabit fosters this infectious disease, which tightens its grip on communities already cut off from adequate healthcare services. The World Health Organization’s (WHO) Sightsavers, and Kenya’s Ministry of Health are working to tackle the disease, but for communities like Rumosiroi’s, the struggle is unrelenting.

173759-Pascal, a Community Drug Distributor (CDD), hands azithromycin tablets to Abedi during a Mass Drug Administration (MDA) in Kajaido, near the Kenyan-Tanzania border. Credit: Sightsavers/Samuel Otieno

Pascal, a Community Drug Distributor (CDD), hands azithromycin tablets to a woman identified as Abedi during a Mass Drug Administration (MDA) in Kajaido, near the Kenyan-Tanzania border. Credit: Sightsavers/Samuel Otieno

In Kenya’s harsh, sun-baked lands of Kenya’s Rift Valley and the north, where water sources are scarce and sanitation is poor, trachoma—a neglected tropical disease caused by Chlamydia trachomatis—leads to chronic suffering and blindness, affecting pastoralist communities who rely on livestock for survival. Addressing trachoma is essential to achieving the United Nations Sustainable Development Goals (SDGs) by 2030, specifically SDG 3, which aims to provide universal health coverage, including access to quality healthcare and affordable medicines.

Elsewhere, at Chemolingot Hospital in East Pokot, Baringo County, a group of elderly women sits in the courtyard, not for medical care but to collect relief food distributed by the county government. Six frail figures lean heavily on walking sticks, guided by young boys to the right spot. Each woman is blind, their sight stolen by trachoma. With red, swollen eyes, they rub incessantly, trying to ease the relentless pain that marks their faces with lines of resignation and fatigue.

“They’ve given me so much eye ointment,” mutters Kakaria Malimtich, her voice tired and defeated. “I don’t even care about treatment anymore—now, it’s just about getting food.”

Malimtich, like many here, has lost her battle with trachoma, which afflicts 1.9 million people globally, primarily in poor regions. In the arid lands of Baringo, people battle blindness along with hunger, poverty, and a lack of basic resources.

Julius, a Community Drug Distributor (CDD), educates two women about trachoma and encourages them to take the treatment during a Mass Drug Administration (MDA) in Kajaido, near the Kenyan-Tanzania border. Credit:Sightsavers/Samuel Otieno/

Julius, a Community Drug Distributor (CDD), educates two women about trachoma and encourages them to take the treatment during a Mass Drug Administration (MDA) in Kajaido, near the Kenyan-Tanzania border. Credit:Sightsavers/Samuel Otieno

Cheposukut Lokdap, a 68-year-old resident of Chemolingot, sits nearby, rubbing her eyes to relieve the sharp stinging pain. “It feels like something is cutting into me,” she whispers, half to herself, half to anyone who’ll listen. Two years ago, her remaining vision faded, plunging her into “the dark world.” She remembers that day vividly—the eye she’d relied on to see the sun and shadows finally failed.

Trachoma is prevalent across Kenya, particularly in pastoralist regions like Turkana, Marsabit, Narok, and Wajir. According to WHO, it’s the leading infectious cause of blindness worldwide, yet it remains underfunded and largely overlooked. The disease thrives in communities with limited access to clean water and healthcare—conditions common among pastoralists.

According to April 2024 data from the World Health Organization, approximately 103 million people live in areas endemic to trachoma and are at risk of blindness from the disease.

“Here in Marsabit, clean water is a luxury, not a right,” says 40-year-old Naitore Lekan, whose husband is a cattle herder. “Our children suffer from eye infections all the time, and there’s no proper clinic to take them to. Sometimes we use herbs or hope it heals on its own, but it often doesn’t.” Naitore’s experience highlights broader issues in pastoralist communities, where traditional beliefs and lack of awareness hinder effective treatment and prevention.

She recounts her family’s struggle with trachoma. “My daughter, Aisha, started losing her sight last year. We thought it was just a simple eye infection, but at the clinic, they told us it was trachoma. They gave her antibiotics, but we couldn’t return for follow-up because the clinic is too far and we can’t afford transport.” For families like Naitore’s, the distance to healthcare centers and financial constraints make trachoma treatment challenging.

In Marsabit, community health worker Hassan Diba is determined to fight trachoma. “Awareness is key,” he says. “I travel to different homesteads, teaching families about trachoma, its causes, and prevention. But I can only reach so many people. We need more resources and support to tackle this issue on a larger scale.”

Trachoma’s impact goes beyond health; it disrupts pastoralist families’ economic stability. “When someone in the family is sick, everything stops,” says Rumosiroi. “I can’t go to graze the animals, and if our livestock aren’t healthy, we can’t sell them. Then we can’t buy food or pay school fees.” According to WHO, the economic burden of trachoma deepens poverty, as families divert resources to medical expenses.

Kenya’s health system faces major challenges, particularly in remote pastoralist areas. The government’s commitment to universal health coverage is commendable, yet implementation lags in regions where access to health services is hindered by geography and infrastructure.

Pascal, a Community Drug Distributor (CDD), measures three-year-old Praygod’s height to determine the correct dose of azithromycin syrup during a Mass Drug Administration (MDA) in Kajaido, near the Kenyan-Tanzania border. Credit: Sightsavers/Samuel Otieno

Pascal, a Community Drug Distributor (CDD), measures 3-year-old Praygod’s height to determine the correct dose of azithromycin syrup during a Mass Drug Administration (MDA) in Kajaido, near the Kenyan-Tanzania border. Credit: Sightsavers/Samuel Otieno

“Most health facilities here are understaffed and under-resourced,” says Dr. Wanjiru Kuria, a public health official in Marsabit. “We need to prioritize funding for preventive measures like clean water and sanitation and train health workers to manage trachoma cases. Without these basics, the fight against trachoma won’t succeed.”

Moses Chege, Director of Sightsavers Kenya, explains that “trachoma disproportionately affects the poorest communities, and eliminating it has profound benefits for individuals and their broader communities.” He adds, “Kenya has made significant strides in the fight against trachoma, which is transforming lives—allowing more children to attend school and more adults to work and support their families.”

“The challenge to eliminate trachoma in Kenya is immense—over 1.1 million people remain at risk,” he told IPS. “Keeping hands and faces clean is essential to prevent the spread, but it’s difficult to maintain good hygiene when communities lack access to clean water. For nomadic groups like the Maasai, reaching them with consistent health services is challenging. There’s also a cultural aspect—some Maasai see the presence of houseflies as a sign of wealth and prosperous livestock. However, these flies carry the bacteria that cause trachoma.”

According to Moses Chege, Kenya has the potential to eliminate trachoma through strategic, evidence-based investments and urgent action, joining the ranks of 21 other countries that have already eradicated the disease. Since 2010, Sightsavers Kenya has been a strong partner to the Ministry of Health, distributing over 13 million trachoma treatments, including 1.6 million treatments in 2022 alone to protect Kenyans from the disease.

The recent launch of Kenya’s Neglected Tropical Disease (NTD) master plan by the Ministry of Health is also expected to accelerate efforts in preventing, eradicating, eliminating, and controlling trachoma and other NTDs across the country.

Organizations like Sightsavers and the Ministry of Health have implemented programs to combat trachoma through mass drug administration and education campaigns. These efforts aim not only to treat the infected but also to promote hygiene practices to prevent the disease’s spread. “We’re seeing positive changes,” says Wanjiru. “When communities understand hygiene’s importance and have treatment access, they can break the cycle of trachoma. But it requires commitment from everyone.”

In 2022, Malawi became the first country in Southern Africa to eliminate trachoma, while Vanuatu achieved this milestone as the first Pacific Island nation.

As the world moves closer to the 2030 SDG deadline, addressing trachoma in pastoralist communities is essential for fulfilling the promise of health for all. It demands a multi-faceted approach combining community education, infrastructure development, and equitable healthcare access. For pastoralists like Naitore, Rumosiroi, and Malimtich, these interventions are not just a promise of restored health but a lifeline to a better future.

Note: This article is brought to you by IPS Noram in collaboration with INPS Japan and Soka Gakkai International in consultative status with ECOSOC.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT 2024

ATHENS, Greece, Nov. 13, 2024 (GLOBE NEWSWIRE) — The European Academy of Allergy and Clinical Immunology (EAACI) is proud to announce the inaugural World Anaphylaxis Awareness Day on 21 November 2024. This landmark initiative, held on the opening day of FAAM–EUROBAT 2024 in Athens, Greece, seeks to raise awareness and promote essential steps in preventing and managing anaphylaxis, a severe, potentially life–threatening allergic reaction.

Anaphylaxis affects approximately 1–2% of the global population, with incidents on the rise worldwide. This severe allergic reaction demands immediate medical intervention and often stems from exposure to common allergens, including specific foods, insect stings, medications, or latex. Despite the risks, awareness of anaphylaxis symptoms, causes, and emergency responses remains low. World Anaphylaxis Awareness Day addresses these knowledge gaps and fosters a global understanding of this critical health issue.                                                   

Through various educational activities, World Anaphylaxis Awareness Day will underscore the importance of prompt emergency responses and preventive measures. EAACI invites medical professionals, allergy societies, and stakeholders worldwide to participate and amplify the message within their communities.

In conjunction with this day, EAACI will also release “A Practical Guide for Patients,” a comprehensive resource developed to support patients and caregivers in understanding, managing, and preventing anaphylactic reactions. This guide offers practical insights on identifying triggers, using adrenaline auto–injectors correctly, and creating personalised action plans to manage risk in everyday life.

“We are thrilled to launch World Anaphylaxis Awareness Day as part of FAAM–EUROBAT 2024,” said Dr Maria Torres, EAACI President. “With this initiative, we hope to empower individuals, families, and healthcare providers with the knowledge and tools to prevent and respond to anaphylaxis. This is an essential step toward improving patient care and reducing the impact of this serious health condition.”

FAAM–EUROBAT 2024, EAACI’s renowned Food Allergy and Anaphylaxis Meeting, will run from 21–23 November, featuring global leaders in allergy research and care. World Anaphylaxis Awareness Day will serve as a key moment within the conference to highlight EAACI’s commitment to patient safety and allergy awareness.

For more information on World Anaphylaxis Awareness Day or the “Practical Guide for Patients,” please visit EAACI Anaphylaxis Awareness Day website.

https://eaaci.org/events_meetings/faam–2024/

https://eaaci.org/about–eaaci/

Media Contact:

maria.cubel@eaaci.org
+ 41 44 205 55 39

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c27c467a–b7bf–4bfa–8f57–3cd3111da23b
https://www.globenewswire.com/NewsRoom/AttachmentNg/99c39d50–e140–468f–adbd–7255c9850f7b


GLOBENEWSWIRE (Distribution ID 1001012968)

Bitget Wallet Launches $20M Telegram Mini-App Support Program with Foresight Ventures

VICTORIA, Seychelles, Nov. 13, 2024 (GLOBE NEWSWIRE) — Bitget Wallet, a leading non–custodial Web3 wallet, has launched the Telegram Mini–App Support Program in collaboration with Bitget and Foresight Ventures. This program aims to support the development of innovative projects that enhance Telegram's mini–app ecosystem, creating new opportunities for developers and projects within the thriving digital space. This initiative comes with a $20M fund and aims to foster the growth of the Telegram platform while offering valuable support to developers.

The Telegram Mini–App Support Program offers key benefits for projects aiming to make a significant impact on Telegram's mini–app ecosystem. With a dedicated $20M fund, the initiative supports the development of innovative mini–apps and tools, providing both financial resources and operational support. Bitget Wallet will provide technical including access and guidance to its OmniConnect developer kit as well as operational and marketing support including access to its vast Telegram wallet user base for community building. Selected projects will gain opportunities for strategic partnerships with leading Telegram mini–app projects, potential listings on Bitget, and investment support from Foresight Ventures. This comprehensive approach empowers developers to bring their ideas to life and contribute to the growing digital economy within Telegram's ecosystem.

The program will focus on three key areas: user onboarding and educational tools, which simplify entry for new users through intuitive UI/UX and educational resources; financial and security infrastructure, supporting the development of decentralized exchanges (DEX), NFT trading, and secure asset management features to enhance Telegram's crypto utility; and mini–app ecosystem expansion, promoting the development of gaming, social, entertainment, and other interactive applications. Projects that drive user adoption, active usage, and secure asset storage are encouraged, helping Telegram grow its ecosystem while fostering long–term user engagement.

Bitget Wallet has amassed a user base of over 40 million and now become the most downloaded multi–chain Web3 wallet. It has pioneered the integration of the TON and Telegram ecosystem, partnering with over 40 mini–app projects. A standout success is its investment in Tomarket, a Telegram mini–app on TON, which gained over 40 million users within three months, highlighting Bitget Wallet's strong incubation capabilities. With recent initiatives, like Bitget Wallet Lite — a multi–chain Telegram wallet that quickly became the largest of its kind. With over 8 million users in two weeks — Bitget Wallet offers users a secure way to purchase, manage, and transfer cryptocurrency within Telegram. Additionally, its OmniConnect developer kit enables Telegram Mini Apps to seamlessly connect with Bitget Wallet for transaction signing, DApp interaction, and multi–chain transactions, leveraging Telegram’s nearly one billion users as a robust platform for scaling digital innovations.

Further details regarding the Telegram Mini–App Support Program will be revealed soon. Alvin Kan, COO of Bitget Wallet, announced this program at WalletCon during Devcon 7 Southeast Asia. “This grant reflects our vision to accelerate the growth of the Telegram ecosystem and empower developers to create next–gen solutions that drive active user participation. We believe Telegram provides the ideal platform for developers to reach new users and build impactful applications, and we are excited to see the next wave of innovation emerge from our partnership with prominent projects in this ecosystem.“

To apply for Telegram Mini–App Support Program, please visit: https://t.me/bitgetwalletminiappsupport

About Bitget Wallet:
Bitget Wallet is the home of Web3, uniting endless possibilities in one non–custodial wallet. With over 40 million users, it offers comprehensive on–chain services, including asset management, instant swaps, rewards, staking, trading tools, live market data, a DApp browser, and an NFT marketplace. Designed for everyone from beginners to advanced traders, it supports mnemonic, MPC, and AA wallet options. With connections to over 100 blockchains, 20,000+ DApps, and 500,000+ tokens, Bitget Wallet enables seamless multi–chain trading across hundreds of DEXs and cross–chain bridges, along with a $300 million protection fund for your digital assets.

Experience Bitget Wallet Lite and follow Bitget Wallet Lite News for updates.

For more information, visit: Twitter | Telegram | Instagram | YouTube | LinkedIn | TikTok | Discord

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e05f6531–5f7b–46b6–83fc–12469e860de3


GLOBENEWSWIRE (Distribution ID 1001012956)